Group 1 (n = 38) | Group 2 (n = 72) | Total (n = 110) | |
---|---|---|---|
23 (60.5%) | 36 (50%) | 59 (53.6%) | |
8 (21.1%) | 28 (38.9%) | 36 (32.7%) | |
6 (15.8%) | 7 (9.7%) | 13 (11.8%) | |
1 (2.6%) | 1 (1.4%) | 2 (1.9%) | |
14 (36.8%) | 35 (48.6%) | 49 (44.5%) |
Group 1 (n = 38) | Group 2 (n = 72) | Total (n = 110) | |
---|---|---|---|
22 (57.9%) | 43 (59.7%) | 65 (59.1%) | |
12 (31.6%) | 24 (33.3%) | 36 (32.7%) | |
3 (7.9%) | 3 (4.2%) | 6 (5.5%) | |
1 (2.6%) | 2 (2.8%) | 3 (2.7%) | |
15 (39.5%) | 27 (37.5%) | 42(38.2%) |
Variables | All cohort (n = 110) | Group 1 (n = 38) | Group 2 (n = 72) | p-value |
---|---|---|---|---|
Age (years) Median (range) | 67 (43−85) | 67 (48−80) | 67 (43−85) | p = 0.51 |
Clinical stage | ||||
cT1a N0 | 2 (1.8%) | 1 (2.6%) | 1 (1.4%) | |
cT1b N0 | 47 (42.8%) | 20 (52.6%) | 27 (37.5%) | |
cT1c N0 | 59 (53.6%) | 17 (44.8%) | 42 (58.3%) | p = 0.42 |
cT1b N1 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
cT2 N0 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
Histological type | ||||
Ductal carcinoma in situ (DCIS) | 1 (0.9%) | 1 (2.6%) | 0 (0.0%) | |
Invasive ductal carcinoma | 70 (63.6%) | 26 (68.4%) | 44 (61.1%) | p = 0.46 |
Invasive lobular carcinoma | 19 (17.3%) | 5 (13.2%) | 14 (19.45%) | |
Others | 20 (18.2%) | 6 (15.8%) | 14 (19.45%) | |
Multifocal disease | 6 (5.4%) | 4 (10.5%) | 2 (2.8%) | p = 0.21 |
Pathological Stage pT | ||||
pTis | 1 (0.9%) | 1 (2.6%) | 0 (0.0%) | |
pT1a | 3 (2.7%) | 0 (0.0%) | 3 (4.2%) | |
pT1b | 41 (37.3%) | 16 (42.1%) | 25 (34.7%) | p=0.40 |
pT1c | 59 (53.6%) | 20 (52.6%) | 39 (54.2%) | |
pT2 | 6 (5.5%) | 1 (2.6%) | 5 (6.9%) | |
Pathological Stage pN | ||||
pN0 | 88 (80.0%) | 32 (84.2%) | 56 (77.8%) | |
pN1mi | 7 (6.4%) | 3 (7.9%) | 4 (5.6%) | p=0.71 |
pN1a | 14 (12.7%) | 3 (7.9%) | 11 (15.3%) | |
pN3 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
Grading | ||||
G1 | 15 (13.7%) | 7(18.4%) | 8 (11.1%) | |
G2 | 68 (61.8%) | 24 (63.2%) | 44 (61.1%) | p = 0.67 |
G3 | 21 (19.1%) | 6 (15.8%) | 15 (20.8%) | |
Gx | 6 (5.4%) | 1 (2.6%) | 5 (7%) | |
Adjuvant therapy Calculated on 109 patients |
||||
None | 2 (1.8%) | 0 (0.0%) | 2 (2.8%) | |
Chemotherapy | 6 (5.5%) | 2 (5.4%) | 4 (5.6%) | p = 0.92 |
Endocrine therapy | 85 (78%) | 29 (78.4%) | 56 (77.7%) | |
Chemotherapy + Endocrine therapy | 12 (11%) | 4 (10.8%) | 8 (11.1%) | |
Chemotherapy + Trastuzumab | 4 (3.7%) | 2 (5.4%) | 2 (2.8%) |